Publication:
Meningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapy

dc.authorscopusid15132366200
dc.authorscopusid59388665500
dc.authorscopusid56955138100
dc.authorscopusid16244621000
dc.authorscopusid57191333346
dc.authorscopusid16021105100
dc.authorscopusid36604690900
dc.authorwosidDinleyici, Ener/Aaf-8688-2019
dc.authorwosidTufan, Aslı/Abi-3407-2020
dc.authorwosidKaya, Mücahit/Caa-2332-2022
dc.authorwosidNalcacioglu, Hulya/L-1713-2016
dc.authorwosidKılıç, Beltinge/Aah-1412-2020
dc.authorwosidGülhan, Bora/Abd-6606-2020
dc.authorwosidDursun, Ismail/Aaw-7097-2020
dc.contributor.authorTufan, Asli Kavaz
dc.contributor.authorBatibay, Fatma Ozak
dc.contributor.authorAksoy, Gulsah Kaya
dc.contributor.authorGulhan, Bora
dc.contributor.authorKilic, Beltinge Demircioglu
dc.contributor.authorDursun, Ismail
dc.contributor.authorDinleyici, Ener Cagri
dc.contributor.authorIDNalcacioglu, Hulya/0000-0002-0686-9714
dc.contributor.authorIDDinleyici, Ener Cagri/0000-0002-0339-0134
dc.contributor.authorIDKaya, Mücahit/0000-0001-6793-536X
dc.date.accessioned2025-12-11T01:27:25Z
dc.date.issued2024
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Tufan, Asli Kavaz; Batibay, Fatma Ozak; Cetin, Nuran] Eskisehir Osmangazi Univ, Fac Med, Dept Pediat Nephrol, Eskisehir, Turkiye; [Aksoy, Gulsah Kaya] Akdeniz Univ, Fac Med, Dept Pediat Nephrol, TR-07070 Antalya, Turkiye; [Gulhan, Bora] Hacettepe Univ, Dept Pediat Neurol, Fac Med, TR-06230 Ankara, Turkiye; [Kilic, Beltinge Demircioglu] Gaziantep Univ, Fac Med, Dept Pediat Nephrol, Gaziantep, Turkiye; [Dursun, Ismail] Erciyes Univ, Fac Med, Dept Pediat Nephrol, TR-38280 Kayseri, Turkiye; [Buyukkaragoz, Bahar] Gazi Univ, Fac Med, Dept Pediat Nephrol, TR-06560 Ankara, Turkiye; [Yilmaz, Aysun Caltik] Ankara Etlik City Hosp, Dept Pediat Nephrol, TR-06170 Ankara, Turkiye; [Nalcacioglu, Hulya] Ondokuz Mayis Univ, Fac Med, Dept Pediat Nephrol, TR-55139 Kurupelit, Samsun, Turkiye; [Becerir, Tulay] Pamukkale Univ, Fac Med, Dept Pediat Nephrol, TR-20160 Denizli, Turkiye; [Celegen, Kubra] Kayseri Res & Training Hosp, Dept Pediat Nephrol, TR-38050 Kayseri, Turkiye; [Dinleyici, Meltem] Eskisehir Osmangazi Univ, Fac Med, Dept Social Pediat, TR-26040 Eskisehir, Turkiye; [Kaya, Mucahit] Diagen Biotechnol, TR-06070 Ankara, Turkiye; [Kilic, Omer] Eskisehir Osmangazi Univ, Dept Pediat Infect Dis, Fac Med, Eskisehir, Turkiye; [Dinleyici, Ener Cagri] Eskisehir Osmangazi Univ, Fac Med, Dept Pediat, TR-26040 Eskisehir, Turkiyeen_US
dc.descriptionNalcacioglu, Hulya/0000-0002-0686-9714; Dinleyici, Ener Cagri/0000-0002-0339-0134; Kaya, Mücahit/0000-0001-6793-536X;en_US
dc.description.abstractBackground/Objectives: Eculizumab is a first-line treatment for atypical hemolytic uremic syndrome (aHUS), and patients undergoing eculizumab therapy may become more susceptible to infection caused by Neisseria meningitidis (Nm). While meningococcal vaccination is required for patients undergoing eculizumab therapy, there is limited knowledge about meningococcal carriage in children with aHUS. We aimed to evaluate (1) the prevalence of Nm carriage, (2) serogroup distribution, and (3) the immunization status of children undergoing eculizumab treatment for aHUS. Methods: The Meningo-aHUS study is a prospective, multi-center study evaluating meningococcal carriage in children and adolescents in T & uuml;rkiye receiving eculizumab for aHUS. We noted the age, gender, daycare, school, or university attendance, passive smoking status, previous infection and antibiotic use, and previous immunization history, including meningococcal vaccines, from the medical records of those children with aHUS. We collected nasopharyngeal samples, tested them for Nm using real-time polymerase chain reaction, and performed a serogroup analysis on the positive samples. Results: We collected nasopharyngeal samples from 62 children with aHUS. Out of 62 children, 61 (98.4%) had received at least one dose of the meningococcal vaccine. The median time since the last meningococcal vaccine dose was 15 months (1-59 months). We detected meningococcal carriage in three (4.8%, 95% CI 1.0-13.5) children, and all three strains were non-groupable (NG). No other serogroups were detected. Conclusions: Almost all the children received their risk-group meningococcal immunization, including booster doses. A 4.8% of children with aHUS carried NG meningococci and, no vaccine serogroups were detected. Patients treated with eculizumab remain profoundly susceptible to IMD due to these NG meningococcal strains. The occurrence of breakthrough cases and carriage of Nm, especially NG strains, highlights the significance of maintaining a state of constant alertness, promptly seeking medical attention, and swiftly treating any symptoms that align with IMD, regardless of their vaccination status or antibiotic prophylaxis.en_US
dc.description.sponsorshipEskisehir Osmangazi University Research [THD-2024-3230]; Eskisehir Osmangazi Universityen_US
dc.description.sponsorshipThis study was financially supported by an Eskisehir Osmangazi University Research Grant (THD-2024-3230).en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.3390/children11101164
dc.identifier.issn2227-9067
dc.identifier.issue10en_US
dc.identifier.pmid39457129
dc.identifier.scopus2-s2.0-85207704381
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/children11101164
dc.identifier.urihttps://hdl.handle.net/20.500.12712/43885
dc.identifier.volume11en_US
dc.identifier.wosWOS:001343031900001
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofChildren-Baselen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtypical Hemolytic Uremic Syndromeen_US
dc.subjectEculizumaben_US
dc.subjectNeisseria Meningitidisen_US
dc.subjectChildrenen_US
dc.subjectMeningococcal Vaccinesen_US
dc.subjectMeningococcien_US
dc.subjectNasopharyngeal Colonizationen_US
dc.titleMeningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files